Table 1 Demographics and clinical characteristics of ‘combined’ cohort (N = 235).
From: Role of gene signatures combined with pathology in classification of oropharynx head and neck cancer
Characteristic | Number (percentage or range) |
|---|---|
Median age in years at diagnosis (range) | 57 (35–80) |
Number female (%) | 32 (13.6%) |
HPV status: | |
Overall HPV positive | 116 (49%) |
Method of HPV status determination‘: | |
HPV RNA positive (RNA seq) | 42 |
HPV DNA (ISH) positive | 64 |
p16 immunohistochemistry (IHC) | 10 |
Negative | 98 (46%) |
Unknown | 11 (5%) |
Subsite: | |
Base of tongue | 39 (16.5%) |
Oropharynx* | 142 (60.5%) |
Tonsil | 54 (23%) |
Clinical Stage AJCC 7: | |
I | 10 (4.2%) |
II | 23 (9.7%) |
III | 33 (13.9%) |
IV | 18 (7.6%) |
IVa | 134 (57%) |
IVb | 13 (5.5%) |
IVc | 4 (1.7%) |
Clinical Stage AJCC 8: | |
I | 71 (30%) |
II | 40 (17%) |
III | 44 (19%) |
IV | 9 (4%) |
IVa | 51 (21.8%) |
IVb | 4 (2%) |
IVc | 1 (0.2%) |
NA | 15 (6%) |
Number with more than 10 pack year history (%) | 186 (81%) |
Median pack years of smokers (IQR) | 30 (12–60) |
Number of patients receiving radiotherapy (%) | 177 (75%) |
Number of patients receiving surgery (%) | 57 (24%) |
Number of patients receiving chemotherapy (%) | 110 (47%) |
Median follow up (years) | 2.34 |
Number of events (overall survival) | 83 |
Number of events (recurrence free survival) | 99 |
